300633SZSE

Announcement of Resolutions from the First Extraordinary Shareholders' Meeting of 2026

✨ AI Summary

The first extraordinary shareholders' meeting of Shenzhen Kaili Biomedical Technology Co., Ltd. was held on April 3, 2026. A total of 156 shareholders participated, representing 54.83% of the voting shares. All proposed resolutions regarding the share repurchase plan were approved with over 99% support, ensuring compliance with legal requirements.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Securities Code: 300633
Securities Abbreviation: Kaili Medical
Announcement Number: 2026-007

Shenzhen Kaili Biomedical Technology Co., Ltd.
Announcement of Resolutions from the First Extraordinary Shareholders' Meeting of 2026

Special Reminder:

  1. No resolutions were rejected at this shareholders' meeting.
  2. This meeting did not involve changes to resolutions previously approved by past shareholders' meetings.

I. Meeting Convening and Attendance

(1) Meeting Details

  1. Meeting Time:
    • (1) On-site Meeting: April 3, 2026 (Friday) at 14:30
    • (2) Online Voting: Voting through the Shenzhen Stock Exchange trading system was available from 09:15-09:25, 09:30-11:30, and 13:00-15:00 on April 3, 2026; voting through the Shenzhen Stock Exchange internet system was available at any time from 09:15 to 15:00 on April 3, 2026.
  2. On-site Meeting Location: Meeting Room 121, 1st Floor, Kaili Medical Building, No. 368, Optoelectronic North Road, Guangming District, Shenzhen
  3. Meeting Method: Combination of on-site voting and online voting
  4. Convener: Board of Directors of Shenzhen Kaili Biomedical Technology Co., Ltd.
  5. Chairman: Mr. Chen Zhiqiang
  6. The meeting was convened in accordance with relevant laws, administrative regulations, departmental rules, normative documents, and the company's articles of association.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.